UNI-EN 81:Notification - current report 81
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 81 | / | 2016 | |||||||
| Date of issue: | 2016-08-18 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Notification - current report 81 | |||||||||||
| Official market - legal basis | |||||||||||
| art. 17. 1 MAR. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| In accordance with the provisions of paragraph 38 from the Ordinance on the Prospectuses Sopharma AD hereby advises that it is in contractual relationship with Service Financial Markets EOOD - www.x3news.com and Investor.bg – www.investor.bg and uses these platforms in order to disseminate periodic and other regulated information. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Notification - current report 81.doc Notification - current report 81.doc | Notification - current report 81 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2016-08-18 | Ognian Donev | Executive director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 5.31 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
